Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX) closed at $44.14 in the latest trading session, marking a +2.65% move from the prior day.
Zacks Investment Research10/15/2026Neutral
BSX
Boston Scientific CorpNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$64.33B
P/E Ratio
17.97
EPS
$2.47
Beta
0.57
52W High
$105.65
52W Low
$41.39
50-Day MA
$46.09
200-Day MA
$59.10
Dividend Yield
—
Profit Margin
17.50%
Forward P/E
13.23
PEG Ratio
0.63
About Boston Scientific Corp
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Fundamentals
| Revenue (TTM) | $21.00B |
| Gross Profit (TTM) | $14.53B |
| EBITDA | $5.71B |
| Operating Margin | 22.90% |
| Return on Equity | 15.30% |
| Return on Assets | 6.19% |
| Revenue/Share (TTM) | $14.19 |
| Book Value | $17.23 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | 3.06 |
| EV/Revenue | 3.655 |
| EV/EBITDA | 13.62 |
| Quarterly Earnings Growth (YoY) | 15.10% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $1.45B |
| Float | $1.44B |
| % Insiders | 0.25% |
| % Institutions | 95.21% |
Historical Volatility
HV 10-Day
23.95%
HV 20-Day
22.22%
HV 30-Day
32.92%
HV 60-Day
34.34%
HV Rank
44.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($59.24 target)
8
Strong Buy17
Buy6
HoldLatest News
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX) concluded the recent trading session at $42.04, signifying a +1.11% move from its prior day's close.
Zacks Investment Research10/8/2026Neutral
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Boston Scientific (BSX). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research10/8/2026Positive
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
New operating structure designed to increase efficiency and support continued growth MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M.
PRNewsWire10/7/2026Neutral
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE: BSX).
GlobeNewsWire10/1/2026Neutral
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects
BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.
Zacks Investment Research9/30/2026Positive
Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued Territory
Boston Scientific stock slumped 55% over 12 months, driven by weakness in electrophysiology and WATCHMAN, which comprise only 26% of 2025 sales. Despite headline challenges, 74% of BSX's business grew at a robust 7% in Q2 2026, indicating underlying strength. Management cut 2026 guidance three times, with organic growth lowered to 5-6% and EPS guidance trimmed to $3.28-$3.32, amplifying investor pessimism.
Seeking Alpha9/29/2026Neutral
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Zacks Investment Research9/28/2026Neutral
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
Zacks Investment Research9/21/2026Positive
New Strong Sell Stocks for September 21st
AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.
Zacks Investment Research9/21/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BSX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026